NCT06116786View on ClinicalTrials.gov

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

November 27, 2023

Primary Completion Date

April 14, 2027

Study Completion Date

June 7, 2029

Conditions
Carcinoma, Non-small-Cell Lung
Interventions
DRUG

JNJ-86974680

JNJ-86974680 will be administered.

DRUG

Cetrelimab

Cetrelimab will be administered.

RADIATION

Radiation Therapy

Radiation therapy will be administered.

Trial Locations (13)

8035

RECRUITING

Hosp Univ Vall D Hebron, Barcelona

10032

RECRUITING

Herbert Irving Comprehensive Cancer Center Columbia University Medical Center, New York

12203

COMPLETED

Charite Research Organisation GmbH, Berlin

14203

RECRUITING

Roswell Park Comprehensive Cancer Center, Buffalo

19107

RECRUITING

Thomas Jefferson University, Philadelphia

22031

RECRUITING

Next Virginia, Fairfax

28041

RECRUITING

Hosp. Univ. 12 de Octubre, Madrid

35392

RECRUITING

Universitaetsklinikum Giessen und Marburg GmbH, Giessen

46026

RECRUITING

Hosp. Univ. I Politecni La Fe, Valencia

07601

RECRUITING

Hackensack University Medical Center, Hackensack

03722

RECRUITING

Severance Hospital Yonsei University Health System, Seoul

06351

RECRUITING

Samsung Medical Center, Seoul

08028

RECRUITING

Hosp. Univ. Quiron Dexeus, Barcelona

All Listed Sponsors
lead

Johnson & Johnson Enterprise Innovation Inc.

INDUSTRY